The closure of Bristol Myers Squibb’s viral vector production facility in Libertyville, Illinois, signifies a strategic move to consolidate cell therapy manufacturing operations. This shift to the Devens, Massachusetts facility reflects a cost-effective and scalable manufacturing approach. With a focus on internalizing vector production, the company aims to achieve significant savings through broader restructuring efforts […]